ID   HEC-1-B
AC   CVCL_0294
SY   Hec-1-B; HEC-1B; Hec-1b; HEC1-B; HEC1B; Hec1B
DR   BTO; BTO:0003038
DR   CLO; CLO_0003675
DR   EFO; EFO_0002192
DR   MCCL; MCC:0000184
DR   CLDB; cl1582
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-113
DR   BioGRID_ORCS_Cell_line; 420
DR   BioSample; SAMN03471094
DR   BioSample; SAMN03472427
DR   BioSample; SAMN03473077
DR   BioSample; SAMN10987737
DR   cancercelllines; CVCL_0294
DR   CCRID; 1101HUM-PUMC000105
DR   CCRID; 3101HUMTCHu115
DR   CCRID; 4201HUM-CCTCC00129
DR   CCTCC; GDC0129
DR   Cell_Model_Passport; SIDM01241
DR   ChEMBL-Cells; CHEMBL3308662
DR   ChEMBL-Targets; CHEMBL614817
DR   CLS; 305095
DR   Cosmic; 687552
DR   Cosmic; 809131
DR   Cosmic; 846178
DR   Cosmic; 980635
DR   Cosmic; 1070807
DR   Cosmic; 1177621
DR   Cosmic; 1223486
DR   Cosmic; 1241345
DR   Cosmic; 1576458
DR   Cosmic; 1696757
DR   Cosmic; 2030465
DR   DepMap; ACH-000941
DR   GEO; GSM844557
DR   GEO; GSM887070
DR   GEO; GSM888140
DR   IARC_TP53; 1111
DR   IGRhCellID; HEC1B
DR   JCRB; JCRB1193
DR   JCRB; NIHS0480
DR   KCB; KCB 200551YJ
DR   LiGeA; CCLE_480
DR   PharmacoDB; HEC1B_532_2019
DR   Progenetix; CVCL_0294
DR   PubChem_Cell_line; CVCL_0294
DR   Ubigene; YC-C108
DR   Wikidata; Q54882253
RX   DOI=10.1007/978-4-431-53981-0_1;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=3518877;
RX   PubMed=4678779;
RX   PubMed=6163305;
RX   PubMed=6220172;
RX   PubMed=6174649;
RX   PubMed=12227503;
RX   PubMed=20215515;
RX   PubMed=20218740;
RX   PubMed=20944090;
RX   PubMed=22460905;
RX   PubMed=22710073;
RX   PubMed=25877200;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Microsatellite instability: Instable (MSI) (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; ClinVar=VCV001736936; Zygosity=Heterozygous; Note=Splice donor mutation (DepMap).
CC   Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; None_reported; -; Zygosity=- (PubMed=20944090).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.76%; East Asian, North=92.48%; East Asian, South=6.76%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0480; true.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): ATCC; CCRID; JCRB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11 (JCRB; PubMed=25877200)
ST   D13S317: 11,16 (ATCC; CCRID)
ST   D16S539: 11,12
ST   D18S51: 16,20
ST   D19S433: 13
ST   D21S11: 30,31
ST   D2S1338: 18,19
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 9,11
ST   D8S1179: 13,14
ST   FGA: 21
ST   Penta D: 9,13
ST   Penta E: 11
ST   TH01: 6 (PubMed=25877200)
ST   TH01: 6,7 (ATCC; CCRID; JCRB)
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0293 ! HEC-1-A
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   DOI=10.1007/978-4-431-53981-0_1;
RA   Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T.,
RA   Kawaguchi M.;
RT   "HEC-1 cells: establishment of an in vitro experimental system in
RT   endometrial carcinoma.";
RL   (In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo (2003).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4678779;
RA   Kuramoto H.;
RT   "Studies of the growth and cytogenetic properties of human endometrial
RT   adenocarcinoma in culture and its development into an established
RT   line.";
RL   Acta Obstet. Gynaecol. Jpn. 19:47-58(1972).
//
RX   PubMed=6163305;
RA   Sekiya S., Takamizawa H.;
RT   "Effect of anticancer drugs on in vitro survival of cell lines derived
RT   from various gynecologic tumors.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 33:373-376(1981).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6174649;
RA   Sekiya S., Kawata M., Inaba N., Takamizawa H.;
RT   "Studies on marker substances in cell lines derived from various human
RT   gynecologic tumors.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 34:37-42(1982).
//
RX   PubMed=12227503; DOI=10.1111/j.1749-0774.2002.tb00103.x;
RA   Kuramoto H., Hamano M., Imai M.;
RT   "HEC-1 cells.";
RL   Hum. Cell 15:81-95(2002).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20218740; DOI=10.1177/153303461000900207;
RA   Wang Y.-M., Yang D., Cogdell D., Hu L.-M., Xue F.-X., Broaddus R.,
RA   Zhang W.;
RT   "Genomic characterization of gene copy-number aberrations in
RT   endometrial carcinoma cell lines derived from endometrioid-type
RT   endometrial adenocarcinoma.";
RL   Technol. Cancer Res. Treat. 9:179-189(2010).
//
RX   PubMed=20944090; DOI=10.1126/scitranslmed.3001538;
RA   Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R.,
RA   Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A.,
RA   Lord C.J., Ashworth A., Reis-Filho J.S.;
RT   "PTEN deficiency in endometrioid endometrial adenocarcinomas predicts
RT   sensitivity to PARP inhibitors.";
RL   Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//